<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mayo Clin Proc Innov Qual Outcomes</journal-id><journal-id journal-id-type="iso-abbrev">Mayo Clin Proc Innov Qual Outcomes</journal-id><journal-id journal-id-type="pmc-domain-id">3533</journal-id><journal-id journal-id-type="pmc-domain">mayocpiqs</journal-id><journal-title-group><journal-title>Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes</journal-title></journal-title-group><issn pub-type="epub">2542-4548</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10244365</article-id><article-id pub-id-type="pmcid-ver">PMC10244365.1</article-id><article-id pub-id-type="pmcaid">10244365</article-id><article-id pub-id-type="pmcaiid">10244365</article-id><article-id pub-id-type="pmid">37293510</article-id><article-id pub-id-type="doi">10.1016/j.mayocpiqo.2023.04.002</article-id><article-id pub-id-type="pii">S2542-4548(23)00018-8</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A Closer Look&#8212;Who Are We Screening for Lung Cancer?</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Galang</surname><given-names initials="K">Kristine</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Polychronopoulou</surname><given-names initials="E">Efstathia</given-names></name><degrees>MPH, RS, PhD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Sharma</surname><given-names initials="G">Gulshan</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Nishi</surname><given-names initials="SPE">Shawn P.E.</given-names></name><degrees>MD</degrees><email>spnishi@utmb.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><aff id="aff1"><label>a</label>Department of Internal Medicine, University of Texas Medical Branch&#8211;Galveston, Galveston, TX</aff><aff id="aff2"><label>b</label>Division of Pulmonary, Critical Care and Sleep Medicine, University of Texas Medical Branch&#8211;Galveston, Galveston, TX</aff><aff id="aff3"><label>c</label>Office of Biostatistics, University of Texas Medical Branch&#8211;Galveston, Galveston, TX</aff><aff id="aff4"><label>d</label>Sealy Center on Aging, University of Texas Medical Branch&#8211;Galveston, Galveston, TX</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label><bold>Correspondence:</bold> Address to Shawn P.E. Nishi, MD, Division of Pulmonary, Critical Care Medicine and Sleep Medicine, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555. <email>spnishi@utmb.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>6</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>03</day><month>5</month><year>2023</year></pub-date><volume>7</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">433785</issue-id><fpage>171</fpage><lpage>177</lpage><history><date date-type="received"><day>19</day><month>1</month><year>2023</year></date><date date-type="rev-recd"><day>31</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>5</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>08</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-06-09 17:25:19.853"><day>09</day><month>06</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 The Authors</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Objective</title><p>To evaluate the characteristics of individuals receiving lung cancer screening (LCS) and identify those with potentially limited benefit owing to coexisting chronic illnesses and/or comorbidities.</p></sec><sec><title>Patients and Methods</title><p>In this retrospective study in the United States, patients were selected from a large clinical database who received LCS from January 1, 2019, through December 31, 2019, with at least 1 year of continuous enrollment. We assessed for potentially limited benefit in LCS defined strictly as not meeting the traditional risk factor inclusion criteria (age &lt;55 years or &gt;80 years, previous computed tomography scan within 11 months before an LCS examination, or a history of nonskin cancer) or liberally as having the potential exclusion criteria related to comorbid life-limiting conditions, such as cardiac and/or respiratory disease.</p></sec><sec><title>Results</title><p>A total of 51,551 patients were analyzed. Overall, 8391 (16.3%) individuals experienced a potentially limited benefit from LCS. Among those who did not meet the strict traditional inclusion criteria, 317 (3.8%) were because of age, 2350 (28%) reported a history of nonskin malignancy, and 2211 (26.3%) underwent a previous computed tomography thorax within 11 months before an LCS examination. Of those with potentially limited benefit owing to comorbidity, 3680 (43.9%) were because of severe respiratory comorbidity (937 [25.5%] with any hospitalization for coronary obstructive pulmonary disease, interstitial lung disease, or respiratory failure; 131 [3.6%] with hospitalization for respiratory failure requiring mechanical ventilation; or 3197 [86.9%] with chronic obstructive disease/interstitial lung disease requiring outpatient oxygen) and 721 (8.59%) with cardiac comorbidity.</p></sec><sec><title>Conclusion</title><p>Up to 1 of 6 low-dose computed tomography examinations may have limited benefit from LCS.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations and Acronyms</title><def-item><term id="kwrd0015">COPD</term><def><p>chronic obstructive pulmonary disease</p></def></def-item><def-item><term id="kwrd0025">ILD</term><def><p>interstitial lung disease</p></def></def-item><def-item><term id="kwrd0035">LCS</term><def><p>lung cancer screening</p></def></def-item><def-item><term id="kwrd0045">NLST</term><def><p>National Lung Screening Trial</p></def></def-item><def-item><term id="kwrd0055">USPSTF</term><def><p>United States Preventive Task Force</p></def></def-item></def-list></front><body><p id="p0010">Lung cancer is the second most diagnosed cancer and remains the leading cause of cancer-related death, accounting for approximately 25% of cancer deaths in the United States.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Results from the landmark National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer mortality with an annual low-dose computed tomography, which led to recommendations by the United States Preventive Services Task Force (USPSTF) and coverage for lung cancer screening (LCS).<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref></p><p id="p0015">The focus of LCS has been to identify the highest risk population who develop lung cancer. However, this strategy also tends to identify individuals with severe and often life-limiting comorbidity. Hence, benefits of LCS are highly variable and may lead to unnecessary diagnoses, testing, and treatments in specific populations. Highly comorbid and older populations were shown to experience higher complications during the evaluation of LCS examination findings.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Given a &lt;0.33% absolute risk reduction for LCS, careful patient selection is necessary to ensure that the benefits outweigh the harms.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref></p><p id="p0020">Criteria for LCS inclusion are based on objective risk factors that predispose individuals to the development of lung cancer (age 50-80 years, a 20-pack year smoking history, and have smoked within the past 15 years).<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> These criteria were initially based on the NLST and were recently revised from 30- to 20-pack years, with a starting age of 55-50 years, after modeling studies reported an increase in life-years gained, with a decrease in overdiagnosis in this expanded population.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> Criteria for LCS exclusion are based on elements that may indicate risks that outweighs the benefits but are not clearly defined. The USPSTF generalizes exclusions to individuals with health problems that substantially limits life expectancy or the ability or willingness to undergo curative lung operation&#8211;both are areas for subjective interpretation.<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref></p><p id="p0025">To date, most studies characterized patient demographics and outcomes of those receiving LCS with an assumption that LCS is appropriate in these cohorts. In particular, few studies evaluated potentially life-limiting comorbidities, that is, competing cause of death in those screened. We used the national administrative health claims to identify individuals aged older than18 years, who underwent LCS to characterize and identify patients and evaluate risk factors and/or comorbidities, which may potentially limit benefit from LCS.</p><sec id="sec1"><title>Patient and Methods</title><p id="p0030">This is a retrospective study of LCS use in the United States using Optum deidentified Clinformatics Data Mart. This study was approved by the University of Texas Medical Branch institutional review board, and informed consent was not obtained owing to the nature of the study.</p><p id="p0035">We included all patients who received LCS from January 1, 2019, through December 31, 2019, and had at least 1 year of previous continuous enrollment. Lung cancer screening was identified by current procedural terminology code G0297 or 71271. Non-CT thorax were identified by current procedural terminology codes 71250, 71260, 71270, and 71275. The variables assessed were age, sex, race/ethnicity, US geographic region, hospitalization, and comorbidities in the 12 months before LCS. Comorbidities were defined based on the Elixhauser comorbidity score as previously defined.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref></p><p id="p0040">Next, we assessed individuals who may not meet the LCS criteria based on the following 2 categories: (1) strict inclusion criteria not met in which an individual fell outside the traditional NLST or USPSTF inclusion risk factor(s) (age &lt;55 or &gt;80 years, CT thorax in 11 months before LCS, and a history of nonskin cancer); and (2) liberal exclusion conditions present to investigate less well-defined comorbid life-limiting condition(s) that may attenuate LCS benefit. Patients with the highest risk of developing lung cancer also reported the highest risk of comorbid cardiovascular and respiratory disease. These comorbidities may be life-limiting and adversely shift the benefit:harm ratio. We defined the comorbid life-limiting condition(s) as patients with any of the following: 3 or more hospitalizations; severe respiratory disease (chronic obstructive disease [COPD]/interstitial lung disease [ILD] and either prescribed long-term oxygen therapy or hospitalized for respiratory failure requiring mechanical ventilation); and severe cardiac disease. Severe cardiac disease was defined as a heart failure diagnosis with either 2 or more hospitalizations for decompensated cardiac disease or patients with a cardiac resynchronization/defibrillation device.</p><p id="p0045">Patient and clinical characteristics were summarized as frequencies and percentages or mean &#177; SDs and compared with the &#967;<sup>2</sup> test or <italic toggle="yes">t</italic> tests as appropriate. All analyses were performed using SAS 9.4. The significance level was set at <italic toggle="yes">P</italic> value of less than.05.</p></sec><sec id="sec2"><title>Results</title><p id="p0050">In 2019, 68,129 individuals underwent 69,028 LCS examinations. Of these, 51,551 patients had continuous enrollment in the 12 months before LCS and were analyzed for this study. The <xref rid="tbl1" ref-type="table">Table</xref> summarizes the characteristics of the LCS cohort. Overall, mean &#177; SD age was 67.5 years, approximately half were women (25,448 [49.4%]), and most patients who underwent LCS recorded no hospitalizations in the preceding year.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table</label><caption><p>Characteristics of Patients Who Underwent LCS<xref rid="tbl1fna" ref-type="table-fn">a</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th colspan="1" rowspan="1">All LCS<hr/></th><th colspan="1" rowspan="1">Potentially limited benefit<hr/></th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic></th></tr><tr><th colspan="1" rowspan="1">N=51,551</th><th colspan="1" rowspan="1">n=8391</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age (y), mean &#177; SD</td><td colspan="1" rowspan="1">67.5&#177;5.9</td><td colspan="1" rowspan="1">68.1&#177;6.5</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="4" rowspan="1">Sex, n (%)</td></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td align="char" colspan="1" rowspan="1">25,448 (49.4)</td><td align="char" colspan="1" rowspan="1">4304 (51.3)</td><td align="char" colspan="1" rowspan="1">&lt;.0004</td></tr><tr><td colspan="1" rowspan="1">&#160;Male</td><td align="char" colspan="1" rowspan="1">26,100 (50.6)</td><td align="char" colspan="1" rowspan="1">4087 (48.7)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Unknown</td><td align="char" colspan="1" rowspan="1">3 (&lt;0.01)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="3" rowspan="1">Region, n (%)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Midwest</td><td align="char" colspan="1" rowspan="1">13,578 (26.3)</td><td align="char" colspan="1" rowspan="1">2029 (24.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Northeast</td><td align="char" colspan="1" rowspan="1">8706 (16.9)</td><td align="char" colspan="1" rowspan="1">1304 (15.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;South</td><td align="char" colspan="1" rowspan="1">21,581 (41.9)</td><td align="char" colspan="1" rowspan="1">3923 (46.8)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;West</td><td align="char" colspan="1" rowspan="1">7508 (14.6)</td><td align="char" colspan="1" rowspan="1">1109 (13.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Unknown</td><td align="char" colspan="1" rowspan="1">178 (0.3)</td><td align="char" colspan="1" rowspan="1">26 (0.3)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="3" rowspan="1">Hospitalizations in previous y, n (%)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;0</td><td align="char" colspan="1" rowspan="1">45,948 (89.1)</td><td align="char" colspan="1" rowspan="1">5758 (68.6)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;1</td><td align="char" colspan="1" rowspan="1">4042 (7.8)</td><td align="char" colspan="1" rowspan="1">1566 (18.7)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;2</td><td align="char" colspan="1" rowspan="1">1001 (1.9)</td><td align="char" colspan="1" rowspan="1">517 (6.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;3+</td><td align="char" colspan="1" rowspan="1">550 (1.1)</td><td align="char" colspan="1" rowspan="1">550 (6.6)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Total Elixhauser score, mean &#177; SD<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1">2.0&#177;2.1</td><td colspan="1" rowspan="1">3.5&#177;2.7</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">Comorbidity components, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Chronic obstructive pulmonary disease (yes)</td><td align="char" colspan="1" rowspan="1">5744 (11.1)</td><td align="char" colspan="1" rowspan="1">3900 (46.5)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Interstitial lung disease (yes)</td><td align="char" colspan="1" rowspan="1">53 (0.1)</td><td align="char" colspan="1" rowspan="1">38 (0.45)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Coagulopathy (yes)</td><td align="char" colspan="1" rowspan="1">635 (1.2)</td><td align="char" colspan="1" rowspan="1">203 (2.4)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Congestive heart failure (yes)</td><td align="char" colspan="1" rowspan="1">2641 (5.1)</td><td align="char" colspan="1" rowspan="1">1285 (15.3)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Pulmonary circulation disorders (yes)</td><td align="char" colspan="1" rowspan="1">673 (1.3)</td><td align="char" colspan="1" rowspan="1">334 (4.0)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Hypertension without complications (yes)</td><td align="char" colspan="1" rowspan="1">21,985 (42.6)</td><td align="char" colspan="1" rowspan="1">4588 (54.7)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Hypertension with complications (yes)</td><td align="char" colspan="1" rowspan="1">2852 (5.5)</td><td align="char" colspan="1" rowspan="1">1080 (12.9)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Chronic pulmonary disease (yes)</td><td align="char" colspan="1" rowspan="1">16,151 (31.3)</td><td align="char" colspan="1" rowspan="1">5314 (63.3)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Diabetes without complications (yes)</td><td align="char" colspan="1" rowspan="1">7708 (14.9)</td><td align="char" colspan="1" rowspan="1">1710 (20.4)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Diabetes with complications (yes)</td><td align="char" colspan="1" rowspan="1">5771 (11.1)</td><td align="char" colspan="1" rowspan="1">1416 (16.9)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Renal failure (yes)</td><td align="char" colspan="1" rowspan="1">3113 (6.0)</td><td align="char" colspan="1" rowspan="1">897 (10.7)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Liver disease (yes)</td><td align="char" colspan="1" rowspan="1">1543 (2.9)</td><td align="char" colspan="1" rowspan="1">363 (4.3)</td><td align="char" colspan="1" rowspan="1">&lt;.0001</td></tr></tbody></table><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">LCS, lung cancer screening.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0015">Elixhauser comorbidity components: chronic pulmonary disease, congestive heart failure, valvular disease, pulmonary circulation disorders, peripheral vascular disorders, hypertension, paralysis, other neurological disorders, diabetes-uncomplicated, diabetes-complicated, hypothyroidism, renal failure, liver disease, peptic ulcer disease excluding bleeding, AIDS, lymphoma, metastatic cancer, solid tumor without metastasis, rheumatoid arthritis/collagen vascular diseases, coagulopathy, obesity, weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency anemia, alcohol abuse, drug abuse, psychoses, and depression.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref></p></fn></table-wrap-foot></table-wrap></p><p id="p0055">Next, we looked at individuals who may have potentially limited benefit of LCS. Of all LCS individuals, 8391 (16.3%) did not meet either strict inclusion risk criteria or possessed liberal exclusion conditions. Of those who did not meet strict inclusion, a small portion were because of age (317 [3.8%]), and over a quarter reported a history of nonskin malignancy (2350 [28%]) and/or underwent a previous CT thorax within the previous 11 months (2211 [26.3%]). A high proportion of individuals with COPD, ILD, and congestive heart failure qualified our definition of potentially limited benefit (67.9%, 71.7%, and 48.7%, respectively).</p><p id="p0060">When we compared all LCS individuals with those defined as having potentially limited benefit, the demographic characteristics (average age, sex, and geographic locations) were similar. Overall, only a small portion of those with liberal exclusion(s) criteria were related to cardiac comorbidity (&#8805;3 hospitalizations [550 {6.6%}]; implantable cardiac support device for end-stage heart disease with &#8805;2 hospitalizations/previous year [719 {8.6%}]). However, nearly half experienced severe respiratory disease (3680 [43.9%]). These included hospitalization for respiratory diagnosis of COPD, ILD, or respiratory failure (937 [25.5%]), hospitalization for respiratory failure requiring mechanical ventilation (131 [3.6%]), or COPD/ILD requiring outpatient oxygen (3197 [86.9%]).</p></sec><sec id="sec3"><title>Discussion</title><p id="p0065">Our study reported a significant number of individuals who may not meet the strict inclusion criteria, and up to 1 in 6 individuals undergoing LCS may have potentially limited benefits owing to comorbidity mostly because of severe cardiopulmonary conditions posing as competing cause(s) of death. The high prevalence of severe comorbidities observed when compared with NLST warrant specific discussions and incorporation of comorbidities into screening decisions because they affect the general health status and, based on their severity, may affect the balance of risks and benefits of LCS.</p><p id="p0070">Evidence for screening outside the strict inclusion or liberal exclusion criteria is limited. A recent single-center study reported that 19% of the LCS examinations were performed in individuals who did not meet the traditional USPSTF inclusion criteria, and more than 40% experienced 3 or more comorbidities using a decentralized approach.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> A veteran&#8217;s study reported, on average, individuals who underwent LCS had more than 4 comorbidities with 33.2% experiencing COPD and 16.6% heart disease; however, the data were limited because they did not indicate the severity of the comorbidity.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> The largest published cohort to date examines the American College of Radiology&#8217;s Lung Cancer Screening registry of over a million screened persons and found that 10% did not meet the strict inclusion criteria and included more older persons who smoke.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> These previous studies have limited generalizability because they are centers or registries with dedicated interest and resources for LCS. This study used information from a large real-world, representative cross-sectional cohort in the United States.</p><p id="p0075">We based our liberal exclusion category on the existing comorbidity data shown to potentially limit 5- to 10-year of life expectancy, which may preclude individuals from the LCS benefit. Cardiovascular disease affects 98% of the population who received LCS.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Heart failure (regardless of the ejection fraction) associated with hospitalization has a 5-year 75% mortality and median survival of 2.1 years.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> Individuals with advanced heart disease requiring an implantable cardiac device demonstrate a 5-year mortality of approximately 50% and high rate of hospitalizations.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> This may be the rationale why the NLST excluded individuals with pacemakers.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Among patients with non&#8211;small cell lung cancer, comorbid cardiovascular diseases (heart failure, myocardial infarction, and cardiac arrhythmias) are associated with 1.5-2 times increased mortality, and multiple cardiovascular comorbidities had approximately 2.5 times increased mortality.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref></p><p id="p0080">Respiratory disease is also a common comorbidity among the population who received LCS and may also limit the benefits of LCS. Patients with COPD demonstrate double the risk of developing lung cancer,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> but individuals with severe COPD (GOLD 3-4) reported no mortality benefit with LCS.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> This was because of a higher rate of nonlung cancer deaths mostly related to respiratory and cardiovascular comorbidities, higher rate of complications from the evaluation and treatment of nodules or cancer,<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> and reduced lung cancer operability.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> Finally, the NLST excluded individuals requiring home oxygen supplementation for undisclosed reasons but may be related to poor survival at 5 and 10 years (57% and 24%, respectively) among individuals with COPD.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref></p><p id="p0085">The American Thoracic Society acknowledges choosing whom to screen for LCS is a complex interplay of risk of developing LC, treatment-related harms, and competing the risk of death.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> Proposed strategies that may identify individuals with the best risk:benefit ratio have been exclusion of those with life expectancy less than 5 years<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> or 10 years.<xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref> The National Cancer Institute defines those with high benefit of LCS as if an individual stood to gain 16.2 life days or more and recorded a life expectancy of at least 5 years.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> This same threshold was further supported in microsimulation analyses conducted during development of the most recent CHEST LCS guidelines.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> The NLST excluded those with a medical condition that posed a significant risk of mortality during the 8-year trial period without guidance on how to identify this population.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Critiques of this strategy are numerous. Providers often overestimate, underestimate, or avoid discussing life expectancy with the patients.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> Patients may not value life expectancy in their decision making. Another strategy uses life-gained calculations,<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> such as the Life Years gained from Screening-computed tomography model<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> that calculates the difference in life expectancy with and without LCS, including factors, such as comorbidity and performance status. Determining a specific life-gained threshold is difficult owing to the complexity of maximizing cost, screening efficiency, patient-centered outcomes, and mortality benefits of LCS. Discussion of these results may be important in the shared decision-making process.</p><p id="p0090">Appropriate timing and intervals for LCS are another consideration. The NLST excluded those with previous imaging within 18 months, likely to reduce over imaging. We chose previous 11 months to look for any CT thorax in our study as a conservative interval compared with the more liberal previous 18 months for any CT thorax imaging defined by the NLST. There was a moderate number of LCS in patients who reported another type of CT thorax imaging performed within the previous 11 months. Previous diagnostic CT thorax examinations may be appropriate to review in lieu of repeating LCS examinations more frequently than annually. This can limit the number of imaging examinations and radiation exposure. Less than half of individuals who underwent LCS and CT thorax within the previous 11 months had their examinations performed at the same facility, which may also highlight a need for universal electronic health information exchange.</p><p id="p0095">There were limitations to this study. The biggest limitation is that we did not possess the outcomes of mortality for these patients to determine whether the population defined as potentially limited benefit reported a higher mortality than those without these defined factors. However, we particularly chose risk factors with evidence of increased mortality and did not suspect that the lung cancer screened population with these defined comorbidities were healthier or unlikely to experience different mortality than the populations that were studied. We cannot assess whether ordering providers considered the exclusion criteria. We presume patients had shared decision making with their provider before a decision for the LCS. This should include potential exclusionary criteria, but we cannot assess the quality of this process. Previous studies have shown that shared decision making rarely occurs, and the quality is shown poor at best.<xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref> In addition, we presume individuals with LCS met the eligibility regarding the smoking history. We cannot verify these data. However, smoking history documentation was shown to be extremely unreliable, and given the high rate of not meeting other eligibility criteria, this presumption might underestimate the number of ineligible patients.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> By contrast, the use of risk calculators might have been used for individuals who did not meet the traditional eligibility criteria, which could not be assessed. The use of the Elixhauser comorbidity index correlate with clinical outcomes in retrospective studies of screening for other malignancy but not LCS; in addition, it does not capture the severity of the disease. Finally, results from Optum may not be generalizable to non-Optum health plans. In addition, we cannot exclude the possibility of coding error&#8211;whether the CT scans were ordered for a clinical reason other than LCS.</p><p id="p0100">To our knowledge, this is the first large real-world study to observe carefully and to define and characterize individuals who may have potentially limited benefit of LCS. Further research is needed to help guide clinical decision making in patients with comorbidities in whom LCS may not benefit. The Personalised Lung Cancer Screening study is an ongoing study using simulation models to estimate the effect of comorbidity, functional limitations, and impaired pulmonary function in LCS individuals.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref></p></sec><sec id="sec4"><title>Conclusions</title><p id="p0105">In this large nationally representative sample, we identified 1 of 6 low-dose computed tomography may have limited benefit from LCS owing to competing comorbidities. LCS should include those with both a high risk for cancer and a life expectancy long enough to benefit from screening, evaluation, and treatment. Future studies are needed to discern the association between comorbidities and LCS outcomes and implement standardized measures for incorporating comorbidities in screening decisions.</p></sec><sec sec-type="COI-statement" id="sec5"><title>Potential Competing Interests</title><p id="p0110">The authors report no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="other" id="sref1"><article-title>Key statistics for lung cancer. American Cancer Society. Updated February 14, 2022</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html#:%7E:text=The%20American%20Cancer%20Society's%20estimates,men%20and%2061%2C360%20in%20women" id="intref0010">https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html#:&#8764;:text=The%20American%20Cancer%20Society's%20estimates,men%20and%2061%2C360%20in%20women</ext-link></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Burnett-Hartman</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>Real-world clinical implementation of lung cancer screening-evaluating processes to improve screening guidelines-concordance</article-title><source>J&#160;Gen Intern Med</source><volume>35</volume><issue>4</issue><year>2020</year><fpage>1143</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1007/s11606-019-05539-w</pub-id><pub-id pub-id-type="pmid">31974902</pub-id><pub-id pub-id-type="pmcid">PMC7174472</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="other" id="sref3"><article-title>Final recommendation statement&#8212;lung cancer: screening. US Preventive Services Task Force</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening" id="intref0015">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening</ext-link></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="other" id="sref4"><article-title>National coverage decision&#8212;screening for lung cancer with low dose computed tomography (LDCT). US Centers for Medicare &amp; Medicaid Services</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&amp;NCAId=274" id="intref0020">https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&amp;NCAId=274</ext-link></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Iaccarino</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Wiener</surname><given-names>R.S.</given-names></name></person-group><article-title>Patient-level trajectories and outcomes after low-dose CT screening in the national lung screening trial</article-title><source>Chest</source><volume>156</volume><issue>5</issue><year>2019</year><fpage>965</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2019.06.016</pub-id><pub-id pub-id-type="pmid">31283920</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Aberle</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>C.D.</given-names></name><etal/></person-group><article-title>Reduced lung-cancer mortality with low-dose computed tomographic screening</article-title><source>N&#160;Engl J Med</source><volume>365</volume><issue>5</issue><year>2011</year><fpage>395</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1102873</pub-id><pub-id pub-id-type="pmid">21714641</pub-id><pub-id pub-id-type="pmcid">PMC4356534</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Meza</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Toumazis</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: modeling study for the US Preventive Services Task Force</article-title><source>JAMA</source><volume>325</volume><issue>10</issue><year>2021</year><fpage>988</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.1077</pub-id><pub-id pub-id-type="pmid">33687469</pub-id><pub-id pub-id-type="pmcid">PMC9208912</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Mazzone</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Screening for lung cancer: CHEST guideline and expert panel report</article-title><source>Chest</source><volume>153</volume><issue>4</issue><year>2018</year><fpage>954</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2018.01.016</pub-id><pub-id pub-id-type="pmid">29374513</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Rivera</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Incorporating coexisting chronic illness into decisions about patient selection for lung cancer screening. An official American Thoracic Society research statement</article-title><source>Am J Respir Crit Care Med</source><volume>198</volume><issue>2</issue><year>2018</year><fpage>e3</fpage><lpage>e13</lpage><pub-id pub-id-type="doi">10.1164/rccm.201805-0986ST</pub-id><pub-id pub-id-type="pmid">30004250</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="other" id="sref10"><article-title>Lung cancer screening guidelines. American Cancer Society</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cancer.org/health-care-professionals/american-cancer-society-prevention-early-detection-guidelines/lung-cancer-screening-guidelines.html" id="intref0025">https://www.cancer.org/health-care-professionals/american-cancer-society-prevention-early-detection-guidelines/lung-cancer-screening-guidelines.html</ext-link></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="other" id="sref11"><article-title>Choosing Wisely an initiative of the ABIM Foundation. American Geriatrics Society</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.choosingwisely.org/clinician-lists/american-geriatrics-society-breast-colorectal-prostate-cancer-screening-in-older-adults/" id="intref0030">https://www.choosingwisely.org/clinician-lists/american-geriatrics-society-breast-colorectal-prostate-cancer-screening-in-older-adults/</ext-link></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Elixhauser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Coffey</surname><given-names>R.M.</given-names></name></person-group><article-title>Comorbidity measures for use with administrative data</article-title><source>Med Care</source><volume>36</volume><issue>1</issue><year>1998</year><fpage>8</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1097/00005650-199801000-00004</pub-id><pub-id pub-id-type="pmid">9431328</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>R.</given-names></name><name name-style="western"><surname>Frazier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Angotti</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>N.T.</given-names></name></person-group><article-title>Guideline-recommended lung cancer screening adherence is superior with a centralized approach</article-title><source>Chest</source><volume>161</volume><issue>3</issue><year>2022</year><fpage>818</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2021.09.002</pub-id><pub-id pub-id-type="pmid">34536385</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>N&#250;&#241;ez</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Caverly</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Invasive procedures and associated complications after initial lung cancer screening in a national cohort of veterans</article-title><source>Chest</source><volume>162</volume><issue>2</issue><year>2022</year><fpage>475</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2022.02.031</pub-id><pub-id pub-id-type="pmid">35231480</pub-id><pub-id pub-id-type="pmcid">PMC9424329</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Silvestri</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Burleson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Characteristics of persons screened for lung cancer in the United States: a cohort study</article-title><source>Ann Intern Med</source><volume>175</volume><issue>11</issue><year>2022</year><fpage>1501</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.7326/M22-1325</pub-id><pub-id pub-id-type="pmid">36215712</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Ruparel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quaife</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Evaluation of cardiovascular risk in a lung cancer screening cohort</article-title><source>Thorax</source><volume>74</volume><issue>12</issue><year>2019</year><fpage>1140</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2018-212812</pub-id><pub-id pub-id-type="pmid">31558626</pub-id><pub-id pub-id-type="pmcid">PMC6902068</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsouaka</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes</article-title><source>J&#160;Am Coll Cardiol</source><volume>70</volume><issue>20</issue><year>2017</year><fpage>2476</fpage><lpage>2486</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2017.08.074</pub-id><pub-id pub-id-type="pmid">29141781</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Saxon</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Gilliam</surname><given-names>F.R.</given-names></name><etal/></person-group><article-title>Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study</article-title><source>Circulation</source><volume>122</volume><issue>23</issue><year>2010</year><fpage>2359</fpage><lpage>2367</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.960633</pub-id><pub-id pub-id-type="pmid">21098452</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Bottle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Faitna</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aylin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cowie</surname><given-names>M.R.</given-names></name></person-group><article-title>Five-year survival and use of hospital services following ICD and CRT implantation: comparing real-world data with RCTs</article-title><source>ESC Heart Fail</source><volume>8</volume><issue>4</issue><year>2021</year><fpage>2438</fpage><lpage>2447</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13357</pub-id><pub-id pub-id-type="pmid">33932129</pub-id><pub-id pub-id-type="pmcid">PMC8318487</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Kravchenko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arbeev</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lyerly</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Yashin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akushevich</surname><given-names>I.</given-names></name></person-group><article-title>Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis</article-title><source>Lung Cancer</source><volume>88</volume><issue>1</issue><year>2015</year><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2015.01.006</pub-id><pub-id pub-id-type="pmid">25704956</pub-id><pub-id pub-id-type="pmcid">PMC4375130</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Gamble</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>G.</given-names></name></person-group><article-title>Airflow limitation and mortality during cancer screening in the National Lung Screening Trial: why quantifying airflow limitation matters</article-title><source><italic toggle="yes">Thorax</italic>. Published online March</source><volume>21</volume><year>2023</year><pub-id pub-id-type="doi">10.1136/thorax-2022-219334</pub-id><pub-id pub-id-type="pmid">36456179</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Hopkins</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chiles</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Reduced expiratory flow rate among heavy smokers increases lung cancer risk. Results from the National Lung Screening Trial&#8212;American College of Radiology Imaging Network cohort</article-title><source>Ann Am Thorac Soc</source><volume>14</volume><issue>3</issue><year>2017</year><fpage>392</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1513/AnnalsATS.201609-741OC</pub-id><pub-id pub-id-type="pmid">28076701</pub-id><pub-id pub-id-type="pmcid">PMC5686299</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>R.</given-names></name></person-group><article-title>The potential impact of chronic obstructive pulmonary disease in lung cancer screening: implications for the screening clinic</article-title><source>Expert Rev Respir Med</source><volume>13</volume><issue>8</issue><year>2019</year><fpage>699</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1080/17476348.2019.1638766</pub-id><pub-id pub-id-type="pmid">31274043</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Cranston</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Crockett</surname><given-names>A.J.</given-names></name></person-group><article-title>The relative survival of COPD patients on long-term oxygen therapy in Australia: a comparative study</article-title><source>Respirology</source><volume>9</volume><issue>2</issue><year>2004</year><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1843.2004.00567.x</pub-id><pub-id pub-id-type="pmid">15182275</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="other" id="sref25"><person-group person-group-type="author"><collab>Veterans Health Administration</collab></person-group><article-title>Lung cancer screening saves veterans lives. US Department of Veterans Affairs. Updated March 7, 2018</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.va.gov/health/newsfeatures/2018/march/ldct-screening-enhances-cancer-care-for-veterans.asp" id="intref0035">https://www.va.gov/health/newsfeatures/2018/march/ldct-screening-enhances-cancer-care-for-veterans.asp</ext-link></element-citation></ref><ref id="bib26"><label>26</label><mixed-citation publication-type="other" id="oref26">Choosing Wisely&#174; is an initiative of the ABIM Foundation. Updated July 6, 2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.choosingwisely.org/clinician-lists/#keyword=screening&amp;parentSociety=Society_of_General_Internal_Medicine" id="intref0050q">https://www.choosingwisely.org/clinician-lists/#keyword=screening&amp;parentSociety=Society_of_General_Internal_Medicine</ext-link>. Accessed June 30, 2022.</mixed-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="other" id="sref27"><person-group person-group-type="author"><collab>Society of General Internal Medicine</collab></person-group><article-title>Choosing Wisely&#8212;an initiative of the ABIM Foundation. Updated February 15, 2017</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.choosingwisely.org/clinician-lists/society-general-internal-medicine-cancer-screening-in-adults-with-life-expectancy-less-than-10-years/" id="intref0040">https://www.choosingwisely.org/clinician-lists/society-general-internal-medicine-cancer-screening-in-adults-with-life-expectancy-less-than-10-years/</ext-link></element-citation></ref><ref id="bib28"><label>28</label><mixed-citation publication-type="other" id="oref28">AMDA&#8211;Cancer screenings if life expectancy less than 10 years. Choosing Wisely&#8212;an initiative of the ABIM Foundation. Updated July 6, 2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.choosingwisely.org/clinician-lists/#keyword=screening%26parentSociety=AMDA_%25u2013_The_Society_for_Post-Acute_and_Long-Term_Care_Medicine" id="intref0050a">https://www.choosingwisely.org/clinician-lists/#keyword=screening&amp;parentSociety=AMDA_%u2013_The_Society_for_Post-Acute_and_Long-Term_Care_Medicine</ext-link>. Accessed June 30, 2022.</mixed-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Castle</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Katki</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Chaturvedi</surname><given-names>A.K.</given-names></name></person-group><article-title>Life-gained-based versus risk-based selection of smokers for lung cancer screening</article-title><source>Ann Intern Med</source><volume>171</volume><issue>9</issue><year>2019</year><fpage>623</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.7326/M19-1263</pub-id><pub-id pub-id-type="pmid">31634914</pub-id><pub-id pub-id-type="pmcid">PMC7191755</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Mazzone</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Souter</surname><given-names>L.H.</given-names></name><etal/></person-group><article-title>Screening for lung cancer: CHEST guideline and expert panel report</article-title><source>Chest</source><volume>160</volume><issue>5</issue><year>2021</year><fpage>e427</fpage><lpage>e494</lpage><pub-id pub-id-type="doi">10.1016/J.CHEST.2021.06.063</pub-id><pub-id pub-id-type="pmid">34270968</pub-id><pub-id pub-id-type="pmcid">PMC8727886</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Schoenborn</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Cayea</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pollack</surname><given-names>C.E.</given-names></name></person-group><article-title>Communicating about stopping cancer screening: comparing clinicians&#8217; and older adults&#8217; perspectives</article-title><source>Gerontologist</source><volume>59</volume><issue>suppl 1</issue><year>2019</year><fpage>S67</fpage><lpage>S76</lpage><pub-id pub-id-type="doi">10.1093/geront/gny172</pub-id><pub-id pub-id-type="pmid">31100135</pub-id><pub-id pub-id-type="pmcid">PMC6524758</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Toumazis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bastani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Plevritis</surname><given-names>S.K.</given-names></name></person-group><article-title>Risk-based lung cancer screening: a systematic review</article-title><source>Lung Cancer</source><volume>147</volume><year>2020</year><fpage>154</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2020.07.007</pub-id><pub-id pub-id-type="pmid">32721652</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Redberg</surname><given-names>R.F.</given-names></name></person-group><article-title>Failing grade for shared decision making for lung cancer screening</article-title><source>JAMA Intern Med</source><volume>178</volume><issue>10</issue><year>2018</year><fpage>1295</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2018.3527</pub-id><pub-id pub-id-type="pmid">30105372</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Goodwin</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Nishi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>Y.F.</given-names></name></person-group><article-title>Use of the shared decision-making visit for lung cancer screening among Medicare enrollees</article-title><source>JAMA Intern Med</source><volume>179</volume><issue>5</issue><year>2019</year><fpage>716</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2018.6405</pub-id><pub-id pub-id-type="pmid">30640388</pub-id><pub-id pub-id-type="pmcid">PMC6503565</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Malo</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Margolis</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Evaluating shared decision making for lung cancer screening</article-title><source>JAMA Intern Med</source><volume>178</volume><issue>10</issue><year>2018</year><fpage>1311</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2018.3054</pub-id><pub-id pub-id-type="pmid">30105393</pub-id><pub-id pub-id-type="pmcid">PMC6233759</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Kukhareva</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Caverly</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Inaccuracies in electronic health records smoking data and a potential approach to address resulting underestimation in determining lung cancer screening eligibility</article-title><source>J&#160;Am Med Inform Assoc</source><volume>29</volume><issue>5</issue><year>2022</year><fpage>779</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1093/jamia/ocac020</pub-id><pub-id pub-id-type="pmid">35167675</pub-id><pub-id pub-id-type="pmcid">PMC9006678</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Braithwaite</surname><given-names>D.</given-names></name><name name-style="western"><surname>Karanth</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Slatore</surname><given-names>C.G.</given-names></name><etal/></person-group><article-title>Personalised Lung Cancer Screening (PLuS) study to assess the importance of coexisting chronic conditions to clinical practice and policy: protocol for a multicentre observational study</article-title><source>BMJ Open</source><volume>12</volume><issue>6</issue><year>2022</year><object-id pub-id-type="publisher-id">e064142</object-id><pub-id pub-id-type="doi">10.1136/bmjopen-2022-064142</pub-id><pub-id pub-id-type="pmcid">PMC9226937</pub-id><pub-id pub-id-type="pmid">35732383</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>